ID
45412
Beskrivning
Principal Investigator: Geoffrey Ginsburg, MD, PhD, Institute for Genome Science and Policy, Duke University, Durham, NC, USA MeSH: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000548 The study protocol for both cohorts has been previously described (Journal of Thrombosis and Thrombolysis 2012:1-12). HV1 cohort: Briefly 50 healthy volunteers were exposed to two weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by microarray before and after aspirin exposure. The pre-aspirin samples were profiled on the U133A 2.0 array and the post-aspirin samples were profiled on the U1333plus 2.0 array. HV2 cohort: Briefly 53 healthy volunteers were exposed to four weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by U133plus 2.0 array before and after aspirin exposure.
Länk
Nyckelord
Versioner (1)
- 2022-11-20 2022-11-20 - Chiara Middel
Rättsinnehavare
Geoffrey Ginsburg, MD, PhD, Institute for Genome Science and Policy, Duke University, Durham, NC, USA
Uppladdad den
20 november 2022
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000548 Aspirin Pharmacogenomics
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, sample ID, and sample use variable obtained from the healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV1] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV2] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Sample ID, body site where sample was collected, and analyte type of samples obtained from healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, sample ID, and sample use variable obtained from the healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV1] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV2] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Sample ID, body site where sample was collected, and analyte type of samples obtained from healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
C0680251 (UMLS CUI [1,2])
C1552738 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])